KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Treasury Shares: 2009-2025

Historic Treasury Shares for Novavax (NVAX) over the last 14 years, with Sep 2025 value amounting to $102.7 million.

  • Novavax's Treasury Shares rose 8.23% to $102.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.7 million, marking a year-over-year increase of 8.23%. This contributed to the annual value of $95.9 million for FY2024, which is 3.89% up from last year.
  • As of Q3 2025, Novavax's Treasury Shares stood at $2.3 million, which was up 1.16% from $2.3 million recorded in Q2 2025.
  • Novavax's Treasury Shares' 5-year high stood at $2.3 million during Q3 2025, with a 5-year trough of $408,989 in Q1 2021.
  • Its 3-year average for Treasury Shares is $1.5 million, with a median of $1.4 million in 2024.
  • Data for Novavax's Treasury Shares shows a peak YoY skyrocketed of 1,689.42% (in 2021) over the last 5 years.
  • Novavax's Treasury Shares (Quarterly) stood at $85.1 million in 2021, then rose by 6.53% to $90.7 million in 2022, then rose by 1.77% to $92.3 million in 2023, then rose by 3.89% to $95.9 million in 2024, then increased by 8.23% to $102.7 million in 2025.
  • Its Treasury Shares was $102.7 million in Q3 2025, compared to $102.5 million in Q2 2025 and $101.9 million in Q1 2025.